Always provide the Client Information Sheet with prescription. Carefully consider the potential benefits and risks of OstiCoxib and other treatment options before deciding to use OstiCoxib. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage of OstiCoxib for oral administration in dogs is 2.27 mg/lb (5.0 mg/kg) body weight once daily as needed for ost...
www.fda.gov/reportanimalae
www.VetOne.netFederal law restricts this drug to use by or on the order of a licensed veterinarian.
Firocoxib belongs to the coxib class of non-narcotic, non-steroidal anti-inflammatory drugs. Firocoxib is a white crystalline compound described chemically as 3-(cyclopropylmethoxy)-4-(4-(methylsulfonyl) phenyl)-5,5-dimethylfuranone. The empirical formula is C17H20O5S, and the molecular weight is 336.4. The structural formula is shown below:
The absolute bioavailability of Firocoxib is approximately 38% when administered as a 5 mg/kg oral dose to fasted adult dogs. Firocoxib is rapidly cleared from the blood via hepatic metabolism and fecal excretion (CLsystemic = ~0.4 L/hr/kg). Despite a high level of plasma protein binding (96%), firocoxib exhibits a large volume of distribution (Vdλ of total drug = ~4.6 L/kg) and a terminal elimination half life of 7.8 hours (%CV = 30%). The oral drug absorption process is highly variable among subjects. Co-administration of OstiCoxib with food delays drug absorption (Tmax from 1 to 5 hours) and decreases peak concentrations (Cmax from 1.3 to 0.9 mcg/mL). However, food does not affect the overall oral bioavailability at the recommended dose.
OstiCoxib® are indicated for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.
Always provide the Client Information Sheet with prescription. Carefully consider the potential benefits and risks of OstiCoxib and other treatment options before deciding to use OstiCoxib. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage of OstiCoxib for oral administration in dogs is 2.27 mg/lb (5.0 mg/kg) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. The dogs can be treated with OstiCoxib approximately two hours prior to surgery. The tablets are scored and dosage should be calculated in half tablet increments. OstiCoxib can be administered with or without food.
Dogs with known hypersensitivity to firocoxib should not receive OstiCoxib.
Not for use in humans. Keep this and all medications out of the reach of children. Consult a physician in case of accidental ingestion by humans.
For oral use in dogs only. Use of this product at doses above the recommended 2.27 mg/lb (5.0 mg/kg) in puppies less than seven months of age has been associated with serious adverse reactions, including death (see Animal Safety). Due to tablet sizes and scoring, dogs weighing less than 12.5 lb (5.7 kg) cannot be accurately dosed.
All dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum baseline data is recommended prior to and periodically during administration of any NSAID.
Owners should be advised to observe for signs of potential drug toxicity (see Adverse Reactions and Animal Safety) and be given a Client Information Sheet about OstiCoxib.
To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Felix Pharmaceuticals Private Limited at 1-833-571-1525. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae
Keep OstiCoxib in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.
This product cannot be accurately dosed in dogs less than 12.5 pounds in body weight.
Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
As a class, cyclooxygenase inhibitory NSAIDs may be associated with renal, gastrointestinal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached and monitored. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDS possess the potential to produce gastrointestinal ulceration and/or gastrointestinal perforation, concomitant use of OstiCoxib with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. The concomitant use of protein bound drugs with OstiCoxib has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant, and behavioral medications. The influence of concomitant drugs that may inhibit the metabolism of OstiCoxib has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.
If additional pain medication is needed after the daily dose of OstiCoxib, a non-NSAID class of analgesic may be necessary.
Appropriate monitoring procedures should be employed during all surgical procedures. Anesthetic drugs may affect renal perfusion, approach concomitant use of anesthetics and NSAIDs cautiously. The use of parenteral fluids during surgery should be considered to decrease potential renal complications when using NSAIDs perioperatively.
The safe use of OstiCoxib in pregnant, lactating or breeding dogs has not been evaluated.
Osteoarthritis:In controlled field studies, 128 dogs (ages 11 months to 15 years) were evaluated for safety when given firocoxib chewable tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally once daily for 30 days. The following adverse reactions were observed. Dogs may have experienced more than one of the observed adverse reactions during the study.
Adverse Reactions Seen in U.S. Field Studies
| Adverse Reactions | Firocoxib n=128 | Active Control n=121 |
| Vomiting | 5 | 8 |
| Diarrhea | 1 | 10 |
| Decreased Appetite or Anorexia | 3 | 3 |
| Lethargy | 1 | 3 |
| Pain | 2 | 1 |
| Somnolence | 1 | 1 |
| Hyperactivity | 1 | 0 |
Firocoxib chewable tablets were safely used during field studies concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics.
Soft-tissue Surgery:In controlled fieldstudies evaluating soft-tissue postoperative pain and inflammation, 258 dogs (ages 10.5 weeks to 16 years) were evaluated for safety when given firocoxib chewable tablets at a dose of 2.27 mg/lb (5.0mg/kg) orally approximately 2 hours prior to surgery and once daily thereafter for up to two days. The following adverse reactions were observed. Dogs may have experienced more than one of the observed reactions during the study.
Adverse Reactions Seen in the Soft-tissue Surgery Postoperative Pain Field Studies
| Adverse Reactions | Firocoxib Group n=127 | Control Group* n=131 |
| Vomiting | 5 | 6 |
| Diarrhea | 1 | 1 |
| Bruising at Surgery Site | 1 | 1 |
| Respiratory Arrest | 1 | 0 |
| SQ Crepitus in Rear Leg and Flank | 1 | 0 |
| Swollen Paw | 1 | 0 |
*Sham-dosed (pilled)
Orthopedic Surgery: Ina controlled field study evaluating orthopedic postoperative pain and inflammation, 226 dogs of various breeds, ranging in age from 1 to 11.9 years in the firocoxib-treated groups and 0.7 to 17 years in the control group were evaluated for safety. Of the 226 dogs, 118 were given firocoxib chewable tablets at a dose of 2.27 mg/lb (5.0 mg/kg) orally approximately 2 hours prior to surgery and once daily thereafter for a total of three days. The following adverse reactions were observed. Dogs may have experienced more than one of the observed reactions during the study.
Adverse Reactions Seen in the Orthopedic Surgery Postoperative Pain Field Study
| Adverse Reactions | Firocoxib Group n=118 | Control Group* n=108 |
| Vomiting | 1 | 0 |
| Diarrhea | 2** | 1 |
| Bruising at Surgery Site | 2 | 3 |
| Inappetence/Decreased Appetite | 1 | 2 |
| Pyrexia | 0 | 1 |
| Incision Swelling, Redness | 9 | 5 |
| Oozing Incision | 2 | 0 |
A case may be represented in more than one category.
*Sham-dosed (pilled).
**One dog had hemorrhagic gastroenteritis.
Post-Approval Experience (Rev. 2009):The following adverse reactions are based on post-approval adverse drug event reporting. The categories are listed in decreasing order of frequency by body system:
Gastrointestinal: vomiting, anorexia, diarrhea, melena, gastrointestinal perforation, hematemesis, hematochezia,weight loss, gastrointestinal ulceration, peritonitis, abdominal pain, hypersalivation, nausea
Urinary:elevated BUN, elevated creatinine, polydypsia, polyuria, hematuria, urinary incontinence, proteinuria, kidney failure, azotemia, urinary tract infection
Neurological/Behavioral/Special Sense:depression/lethargy, ataxia, seizures, nervousness, confusion, weakness,hyperactivity, tremor, paresis, head tilt, nystagmus, mydriasis, aggression, uveitis.
Hepatic:elevated ALP, elevated ALT, elevated bilirubin, decreased albumin, elevated AST, icterus, decreased or increased total protein and globulin, pancreatitis, ascites, liver failure, decreased BUN
Hematological:anemia, neutrophilia, thrombocytopenia, neutropenia
Cardiovascular/Respiratory:tachypnea, dyspnea, tachycardia
Dermatologic/Immunologic:pruritis, fever, alopecia, moist dermatitis, autoimmune hemolytic anemia, facial/muzzle edema, urticaria
In some cases, death has been reported as an outcome of the adverse events listed above.
To report suspected adverse drug events, for technical assistance or to obtain a copy of Safety Data Sheet, contact Felix Pharmaceuticals Private Limited at 1-833-571-1525. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae
Firocoxib, like other drugs of its class, is not free from adverse reactions. Owners shouldbe advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance.Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption,increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy,incoordination, seizure, or behavioral changes.
Serious adverse reactions associated with this drug class can occur without warning and in rare situationsresult in death (see Adverse Reactions). Owners should be advised to discontinue OstiCoxib therapy and contacttheir veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug relatedadverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate,is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.
Mode of action: Firocoxib is a cyclooxygenase-inhibiting (coxib) class, non-narcotic, non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. There are two main cyclooxygenase enzymes, COX-1 and COX-2, and a newly discovered third enzyme, COX-3, which has yet to be fully characterized.1 Cyclooxygenase-1 (COX-1) is the enzyme responsible for facilitating constitutive physiologic processes, e.g., platelet aggregation, gastric mucosal protection, and renal perfusion.2 It also is constitutively expressed in the brain, spinal cord, and reproductive tract.3 Cyclooxygenase-2 (COX-2) is responsible for the synthesis of inflammatory mediators, but it is also constitutively expressed in the brain, spinal cord and kidneys. 4,5,6 Cyclooxygenase-3 (COX-3) is also constitutively expressed in the canine and human brain and also the human heart. 7 Results from in vitro studies showed firocoxib to be highly selective for the COX-2 enzyme when canine blood was exposed to drug concentrations comparable to those observed following a once daily 5 mg/kg oral dose in dogs.8 However, the clinical significance of these findings has not been established.
Two hundred and forty-nine dogs of various breeds, ranging in age from 11 months to 20 years, and weighing 13 to 175 lbs, were randomly administered firocoxib or an active control drug in two field studies. Dogs were assessed for lameness, pain on manipulation, range of motion, joint swelling, and overall improvement in a non-inferiority evaluation of firocoxib compared with the active control. At the study's end, 87% of the owners rated firocoxib-treated dogs as improved. Eighty-eight percent of dogs treated with firocoxib were also judged improved by the veterinarians. Dogs treated with firocoxib showed a level of improvement in veterinarian-assessed lameness, pain on palpation, range of motion, and owner-assessed improvement that was comparable to the active control. The level of improvement in firocoxib-treated dogs in limb weight bearing on the force plate gait analysis assessment was comparable to the active control.
In a separate field study, two hundred fifty-eight client-owned dogs of various breeds, ranging in age from 10.5 weeks to 16 years and weighing from 7 to 168 lbs, were randomly administered firocoxib or a control (sham-dosed-pilled) for the control of postoperative pain and inflammation associated with soft-tissue surgical procedures such as abdominal surgery (e.g. ovariohysterectomy, abdominal cryptorchidectomy, splenectomy, cystotomy) or major external surgeries (e.g. mastectomy, skin tumor removal ≥8 cm). The study demonstrated that firocoxib-treated dogs had significantly lower need for rescue medication than the control (sham-dosed-pilled) in controlling postoperative pain and inflammation associated with soft-surgery.
A multi-center field study with 226 client-owned dogs of various breeds, and ranging in age from 1 to 11.9 years in the firocoxib-treated groups and 0.7 to 17 years in the control group was conducted. Dogs were randomly assigned to either the firocoxib or the control (sham-dosed-pilled) group for the control of postoperative pain and inflammation associated with orthopedic surgery. Surgery to repair a ruptured cruciate ligament included the following stabilization procedures: fabellar suture and/or imbrication, fibular head transposition, tibial plateau leveling osteotomy (TPLO), and 'over the top' technique. The study (n = 220 for effectiveness) demonstrated that firocoxib-treated dogs had significantly lower need for rescue medication than the control (sham-dosed-pilled) in controlling postoperative pain and inflammation associated with orthopedic surgery.
In a target animal safety study, firocoxib was administered orally to healthy adult Beagle dogs (eight dogs per group) at 5, 15, and 25 mg/kg (1, 3, and 5 times the recommended total daily dose) for 180 days. At the indicated dose of 5 mg/kg, there were no treatment related adverse events. Decreased appetite, vomiting, and diarrhea were seen in dogs in all dose groups, including unmedicated controls, although vomiting and diarrhea were seen more often in dogs in the 5X dose group. One dog in the 3X dose group was diagnosed with juvenile polyarteritis of unknown etiology after exhibiting recurrent episodes of vomiting and diarrhea, lethargy, pain, anorexia, ataxia, proprioceptive deficits, decreased albumin levels, decreased and then elevated platelet counts, increased bleeding times, and elevated liver enzymes. Onhistopathologic examination, a mild ileal ulcer was found in one 5X dog. This dog also had a decreased serum albuminwhich returned to normal by study completion. One control and three 5X dogs had focal areas of inflammation in thepylorus or small intestine. Vacuolization without inflammatory cell infiltrates was noted in the thalamic region of the brainin three control, one 3X, and three 5X dogs. Mean ALP was within the normal range for all groups but was greater in the3X and 5X dose groups than in the control group. Transient decreases in serum albumin were seen in multiple animalsin the 3X and 5X dose groups, and in one control animal.
In a separate safety study, firocoxib was administered orally to healthy juvenile (10-13 weeks of age) Beagle dogs at 5,15, and 25 mg/kg (1, 3, and 5 times the recommended total daily dose) for 180 days. At the indicated (1X) dose of 5 mg/kg, onhistopathologic examination, three out of six dogs had minimal periportal hepatic fatty change. On histopathologicexamination, one control, one 1X, and two 5X dogs had diffuse slight hepatic fatty change. These animals showed no clinicalsigns and had no liver enzyme elevations. In the 3X dose group, one dog was euthanized because of poor clinical condition(Day 63). This dog also had a mildly decreased serum albumin. At study completion, out of five surviving and clinically normal 3X dogs, three had minimal periportal hepatic fatty change. Of twelve dogs in the 5X dose group, one died (Day 82)and three moribund dogs were euthanized (Days 38, 78, and 79) because of anorexia, poor weight gain, depression, and inone dog, vomiting. One of the euthanized dogs had ingested a rope toy. Two of these 5X dogs had mildly elevated liverenzymes. At necropsy all five of the dogs that died or were euthanized had moderate periportal or severe panzonal hepaticfatty change; two had duodenal ulceration; and two had pancreatic edema. Of two other clinically normal 5X dogs (out of foureuthanized as comparators to the clinically affected dogs), one had slight and one had moderate periportal hepatic fattychange. Drug treatment was discontinued for four dogs in the 5X group. These dogs survived the remaining 14 weeks of thestudy. On average, the dogs in the 3X and 5X dose groups did not gain as much weight as control dogs. Rate of weight gainwas measured (instead of weight loss) because these were young growing dogs. Thalamic vacuolation was seen in three ofsix dogs in the 3X dose group, five of twelve dogs in the 5X dose group, and to a lesser degree in two unmedicated controls.Diarrhea was seen in all dose groups, including unmedicated controls.
In a separate dose tolerance safety study involving a total of six dogs (two control dogs and four treated dogs), firocoxibwas administered to four healthy adult Beagle dogs at 50 mg/kg (ten times the recommended daily dose) for twenty-twodays. All dogs survived to the end of the study. Three of the four treated dogs developed small intestinal erosion or ulceration.Treated dogs that developed small intestinal erosion or ulceration had a higher incidence of vomiting, diarrhea, anddecreased food consumption than control dogs. One of these dogs had severe duodenal ulceration, with hepatic fattychange and associated vomiting, diarrhea, anorexia, weight loss, ketonuria, and mild elevations in AST and ALT. All fourtreated dogs exhibited progressively decreasing serum albumin that, with the exception of one dog that developedhypoalbuminemia, remained within normal range. Mild weight loss also occurred in the treated group. One of the two control dogs and three of the four treated dogs exhibited transient increases in ALP that remained within normal range.
Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C (between 59° to 86°F) [See USP Controlled Room Temperature].
To Request a Safety Data Sheet (SDS), call 1-833-571-1525.
OstiCoxib is available as round, brownish yellow to pale brown, half-scored tablets in two strengths, containing 57 mg or 227 mg firocoxib. Each tablet strength is supplied in 30 count blister packages, 60 count and 180 count bottles.
NDC Number | Tablet Size | Package Description |
86136-153-36 | 57 mg | 60 in Bottle pack |
86136-153-65 | 57 mg | 180 in Bottle pack |
XXXXX-XXX-XX | 57 mg | 30 in Blister pack |
| 86136-155-36 | 227 mg | 60 in Bottle pack |
86136-155-65 | 227 mg | 180 in Bottle pack |
XXXXX-XXX-XX | 227 mg | 30 in Blister pack |
1Willoughby DA, Moore AR and Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355: 646-648.
2Smith, et al., Pharmacological Analysis of Cyclo-oxygenase-1 in Inflammation. Proc. Natl. Acad. Sci. USA, Pharmacology 1998; 95: 13313-13318.
3Jones CJ and Budsberg SC. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. JAVMA 2000; 217(5): 721-729.
4Zhang, et al., Inhibition of Cyclo-oxygenase-2 Rapidly Reverses Inflammatory Hyperalgesia and Prostaglandin E2 Production. JPET 1997; 283: 1069-1075.
5Jones and Budsberg, pp. 721-729.
6Zhang, et al., pp. 1069-1075.
7Chandrasekharan NV, Dai H, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure and expression. Proc. Natl. Acad. Sci. USA, 2002; 99(21): 13926-13931.
8Data on file with NADA # 141-230.
Distributed by:
MWI
Boise, ID 83705
www.VetOne.net
Made in India
Neutral Code No. MP/DRUGS/25/90/2020
Rev. 09/2026
Approved by FDA under ANADA # 200-755
OstiCoxib are used for the control of pain and inflammationdue to osteoarthritis or associated with soft-tissue and orthopedic surgery inyour dog.
This summary contains important information about OstiCoxib. You should read thisinformation before you start giving your dog OstiCoxiband review it each timeyour prescription is refilled. This sheet is provided only as a summary and does not takethe place of instructions from your veterinarian. Talk to your veterinarian if you do notunderstand any of this information or you want to know more about OstiCoxib .
What is OstiCoxib?
OstiCoxib is a veterinary prescription non-steroidal anti-inflammatory drug (NSAID) used to control pain and inflammation due to osteoarthritis, or associated with soft-tissue and orthopedic surgery in dogs.
Osteoarthritis is a painful condition caused by " wear and tear" of cartilage and other parts of the joints that may result in the following changes or signs in your dog:
OstiCoxib is indicated for the control of postoperative pain and inflammation followingsoft-tissue and orthopedic surgeries (e.g. spays, cruciate ligament repair). Yourveterinarian may administer OstiCoxibbefore the procedure and recommend that thedog be treated for a few days after going home.
What kind of results can I expect when my dog is on OstiCoxib forosteoarthritis?
WhileOstiCoxib is not a cure for osteoarthritis, it can control the pain and inflammationand improve your dog's mobility.
• Response varies from dog to dog, but improvement can be quite dramatic.
• In most dogs, improvement can be seen within days.
• IfOstiCoxib is discontinued or not given as directed, your dog's pain andinflammation may return.
What kind of results can I expect when my dog is onOstiCoxib for the control ofpain and inflammation following soft-tissue and orthopedic surgery?
• OstiCoxiballow your dog to recover more comfortably bycontrolling pain and inflammation following soft-tissue and orthopedic surgery.
• Control of pain and inflammation may vary from dog to dog.
• IfOstiCoxib are not given according to your veterinarian'sdirections, your dog's pain may return.
• Consult your veterinarian if your dog appears to be uncomfortable.
Which dogs should not take OstiCoxib?
Your dog should not be givenOstiCoxib if he/she:
• Has an allergic reaction to firocoxib, the active ingredient in OstiCoxib.
• Has had an allergic reaction (such as hives, facial swelling, or red or itchy skin) to aspirin or other NSAIDs.
• Is presently taking aspirin, other NSAIDs, or corticosteroids.
• Is under 12.5 pounds in body weight.
• Has pre-existing kidney or liver disease.
• Has decreased appetite, vomiting or diarrhea.
OstiCoxib should only be given to dogs.
People should not take OstiCoxib. Keep OstiCoxib and all medications out of the reach of children. Call your physician immediately if you accidentally take OstiCoxib.
What to tell/ask your veterinarian before giving OstiCoxib.
Talk to your veterinarian about:
• The signs of osteoarthritis you have observed in your dog, such as limping orstiffness.
• The importance of weight control in the management of osteoarthritis.
• What tests might be done before OstiCoxibis prescribed.
• How often your dog may need to be examined by your veterinarian.
• The risks and benefits of using OstiCoxib. Serious adverse reactions, includingdeath, have been associated with Firocoxib administration at doses above therecommended dose in puppies less than seven months of age.
Tell your veterinarian if your dog is currently experiencing or has ever had the followingmedical problems:
• Any side effects from taking OstiCoxibor other NSAIDs, such as aspirin.
• Any digestive upset (vomiting and/or diarrhea).
• Any kidney disease.
• Any liver disease.
Tell your veterinarian about:
• Any other medical problems or allergies that your dog has now, or has had in the past.
• All medicines that you are giving or plan to give to your dog, including those you can get without a prescription and any dietary supplements.
Tell your veterinarian if your dog:
• Is under 7 months of age.
• Is pregnant, nursing or if you plan to breed your dog.
How to give OstiCoxibto your dog.
OstiCoxib should be given according to your veterinarian′s instructions. Do not changethe way you giveOstiCoxib to your dog without first speaking with your veterinarian.Your veterinarian will tell you what amount ofOstiCoxib is right for your dog and for howlong it should be given. OstiCoxibmay be offered to the dog by hand,or you can place the tablet in your dog’s mouth.OstiCoxib may be given with or without food.
What are the possible side effects that may occur in my dog duringOstiCoxib therapy?
OstiCoxib, like other NSAIDS, may cause some side effects. Serious side effectsassociated with NSAID therapy in dogs can occur with or without warning, and, in raresituations, result in death. The most common side effects associated withOstiCoxib therapy involve the digestive tract (vomiting and decreased food consumption). Liver andkidney problems have also been reported with NSAIDs. Look for the following side effects that may indicate your dog is having a problem with OstiCoxib:
• Decrease or increase in appetite.
• Vomiting.
• Change in bowel movements (such as diarrhea, or black, tarry or bloody stools).
• Change in behavior (such as decreased or increased activity level, incoordination,seizure, or aggression).
• Yellowing of gums, skin, or whites of the eyes (jaundice).
• Change in drinking habits (frequency or amount consumed).
• Change in urination habits (frequency, color, or smell).
• Change in skin (redness, scabs, or scratching).
• Unexpected weight loss.
It is important to stop the medication and contact your veterinarian immediately if youthink your dog has a medical problem or side effect while taking OstiCoxib. If youhave additional questions about possible side effects, talk with your veterinarian or call 1-833-571-1525.
CanOstiCoxib be given with other medications?
OstiCoxibshould not be given with other NSAIDs (for example, aspirin, carprofen,etodolac, deracoxib, meloxicam, or tepoxalin) or corticosteroids (for example,prednisone, cortisone, dexamethasone, or triamcinolone).
Tell your veterinarian about all medications that you have given your dog in the past,and any medications you are planning to give with OstiCoxib. This shouldinclude other medicines that you can get without a prescription or any dietarysupplements. Your veterinarian may want to check that all of your dog's medicines canbe given together.
What do I do in case my dog eats more than the prescribed amount of OstiCoxib?
Consult your veterinarian immediately if your dog eats more than the prescribedamount of OstiCoxib.
What else should I know about OstiCoxib?
• This sheet provides a summary of information about OstiCoxib. If you haveany questions or concerns about OstiCoxib, osteoarthritis pain, or postoperative painfollowing soft-tissue and orthopedic surgery, talk with your veterinarian.
• As with all prescribed medicines,OstiCoxib should only be given to the dogfor which they were prescribed. They should be given to your dog only for thecondition for which they were prescribed, at the prescribed dose.
• It is important to periodically discuss your dog's response to OstiCoxib. Your veterinarian will determine if your dog is responding as expected and ifyour dog should continue receiving OstiCoxib.
Contact Information:
To report suspected adverse drug events, for technical assistance or toobtain a copy of Safety Data Sheet, contact Felix Pharmaceuticals PrivateLimited at 1-833-571-1525. For additional information about adverse drugexperience reporting for animal drugs, contact FDA at 1-888-FDA-VETS orwww.fda.gov/reportanimalae
Approved by FDA under ANADA # 200-755
Distributed by:
MWI
Boise, ID 83705
www.VetOne.net
Made in India
Neutral Code No. MP/DRUGS/25/90/2020
Rev. 09/2026
NDC: 86136-153-36
OstiCoxib
(firocoxib chewable tablets)
57 mg
Coxib-class non-steroidal anti-inflammatory drug
For Oral Use in Dogs Only
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-755
60 Chewable Tablets
NDC: 86136-153-65
OstiCoxib
(firocoxib chewable tablets)
57 mg
Coxib-class non-steroidal anti-inflammatory drug
For Oral Use in Dogs Only
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-755
180 Chewable Tablets
NDC: 86136-155-36
OstiCoxib
(firocoxib chewable tablets)
227 mg
Coxib-class non-steroidal anti-inflammatory drug
For Oral Use in Dogs Only
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-755
60 Chewable Tablets
NDC: 86136-155-65
OstiCoxib
(firocoxib chewable tablets)
227 mg
Coxib-class non-steroidal anti-inflammatory drug
For Oral Use in Dogs Only
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-755
180 Chewable Tablets
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0386136153361 | GTIN-13: 0386136153361 EAN-13: 0386136153361 GTIN-12: 386136153361 UPC-A: 386136153361 GTIN storage (14 digits): 00386136153361 | bottel1.jpg |
| Data code | Data Matrix | ED_HAYES Oracle123 | container3.jpg, bottel1.jpg, container2.jpg, container4.jpg |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 86136-153 | 86136-153-36, 86136-153-65 |
| 86136-155 | 86136-155-36, 86136-155-65 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| FIROCOXIB | Y6V2W4S4WT | ACTIB |
| FIROCOXIB | Y6V2W4S4WT | ACTIB |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 2 | 2026-09-17 | daily-update | 2026-09-22 03:00:57 |
| 1 | 2026-03-16 | full-release | 2026-06-01 02:46:38 |
Adverse event summaries are temporarily unavailable. Other product information remains available.